NeuroXT Inc.

New Capabilities

Holder of FDA 510(k) K261805 for NEXT-Cue

For years, software that reads a brain scan has been cleared to report what is visible now: a bleed, a lesion, a narrowed vessel. NEXT-Cue is cleared to report something else — how likely a patient already diagnosed with mild cognitive impairment is to develop Alzheimer's dementia within five years.

Updated 1 hour ago